ImmunoBON voted Most Innovative Product of 2021

RNS Number : 9294L

Allergy Therapeutics PLC

16 September 2021

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

ImmunoBON voted Most Innovative Product of 2021 at Pharma Trend Image and Innovation Awards in Germany

16 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, is pleased to announce that ImmunoBON, the Group's patented protein-based oral product for the general treatment of allergies, has been voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards in Germany.

The awards, held every year, are based on the Pharma Trend benchmark study, which seeks the views of 700 physicians, 100 pharmacists and 600 patients in Germany.

ImmunoBON, which Allergy Therapeutics launched in Germany and Austria earlier this year, replicates the reduced allergic reactions seen in people who live on or close to livestock farms - the so called 'farm effect'. It offers an innovative treatment approach for patients with mild allergies, the largest segment of the allergy market.

Latest data support its use as a treatment for birch and house dust mite allergies and Allergy Therapeutics is currently exploring its potential across a broader patient population.

Manuel Llobet, CEO of Allergy Therapeutics , stated: "We are delighted that ImmunoBON has been recognised for its innovative approach to the treatment of allergy patients, particularly as the award is voted for by those we serve - doctors, pharmacists and patients.

"ImmunoBON is an exciting product that provides an over the counter (OTC) option which fits very well with our portfolio philosophy to develop highly differentiated products with specific value added for our patients. Following successful launches in Germany and Austria, we are looking forward to making ImmunoBON available to more patients, through additional country launches, and through research exploring its potential to treat additional allergies".

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Carina Jurs

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

 

END

 

 

NRAKZGMLGKNGMZZ